327 related articles for article (PubMed ID: 30173786)
1. Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota.
Vasco M; Paolillo R; Schiano C; Sommese L; Cuomo O; Napoli C
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):290-300. PubMed ID: 30173786
[TBL] [Abstract][Full Text] [Related]
2. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota in Obesity and Undernutrition.
de Clercq NC; Groen AK; Romijn JA; Nieuwdorp M
Adv Nutr; 2016 Nov; 7(6):1080-1089. PubMed ID: 28140325
[TBL] [Abstract][Full Text] [Related]
5. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
6. A mechanism based approach to management of children with end-stage liver disease.
Haafiz AB
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1085-1094. PubMed ID: 28803487
[TBL] [Abstract][Full Text] [Related]
7. Intestinal microbiota in liver disease.
Haque TR; Barritt AS
Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
[TBL] [Abstract][Full Text] [Related]
9. The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.
Briskey D; Tucker P; Johnson DW; Coombes JS
Clin Exp Nephrol; 2017 Feb; 21(1):7-15. PubMed ID: 26965149
[TBL] [Abstract][Full Text] [Related]
10. Precision Nutrition and the Microbiome Part II: Potential Opportunities and Pathways to Commercialisation.
Mills S; Lane JA; Smith GJ; Grimaldi KA; Ross RP; Stanton C
Nutrients; 2019 Jun; 11(7):. PubMed ID: 31252674
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota and non-alcoholic fatty liver disease.
Gkolfakis P; Dimitriadis G; Triantafyllou K
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
[TBL] [Abstract][Full Text] [Related]
12. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases.
Liu C; Wang YL; Yang YY; Zhang NP; Niu C; Shen XZ; Wu J
FASEB J; 2021 Oct; 35(10):e21871. PubMed ID: 34473374
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota and malnutrition.
Million M; Diallo A; Raoult D
Microb Pathog; 2017 May; 106():127-138. PubMed ID: 26853753
[TBL] [Abstract][Full Text] [Related]
15. Targeting Dysbiosis for the Treatment of Liver Disease.
Anand G; Zarrinpar A; Loomba R
Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
[TBL] [Abstract][Full Text] [Related]
16. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
Leclercq S; de Timary P; Stärkel P
Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
[TBL] [Abstract][Full Text] [Related]
17. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
Yang YJ; Ni YH
J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
[TBL] [Abstract][Full Text] [Related]
19. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
20. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.
Cuevas-Sierra A; Ramos-Lopez O; Riezu-Boj JI; Milagro FI; Martinez JA
Adv Nutr; 2019 Jan; 10(suppl_1):S17-S30. PubMed ID: 30721960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
